Genetic and Pharmacologic Inhibition of mTORC1 Promotes EMT by a TGF-β–Independent Mechanism

Ivan Mikaelian1,2, Mouhannad Malek6, Rudy Gadet1,2, Jean Viallet4,5, Amandine García1,2, Anaïs Girard-Gagnepain1,2, Cédric Hesling1,2, Germain Gillet1,2, Philippe Gonzalo1,2, Ruth Rimokh1,2, and Marc Billaud4

Abstract

Epithelial-to-mesenchymal transition (EMT) is a transdifferentiation process that converts epithelial cells into highly motile mesenchymal cells. This physiologic process occurs largely during embryonic development but is aberrantly reactivated in different pathologic situations, including fibrosis and cancer. We conducted a siRNA screening targeted to the human kinome with the aim of discovering new EMT effectors. With this approach, we have identified mTOR complex 1 (mTORC1), a nutrient sensor that controls protein and lipid synthesis, as a key regulator of epithelial integrity. Using a combination of RNAi and pharmacologic approaches, we report here that inhibition of either mTOR or RPTOR triggers EMT in mammary epithelial cells. This EMT was characterized by the induction of the mesenchymal markers such as fibronectin, vimentin, and PAI-1, together with the repression of epithelial markers such as E-cadherin and ZO-3. In addition, mTORC1 blockade enhanced in vivo migratory properties of mammary cells and induced EMT independent of the TGF-β pathway. Finally, among the transcription factors known to activate EMT, both ZEB1 and ZEB2 were upregulated following mTOR repression. Their increased expression correlated with a marked reduction in miR-200b and miR-200c mRNA levels, two microRNAs known to downregulate ZEB1 and ZEB2 expression. Taken together, our findings unravel a novel function for mTORC1 in maintaining the epithelial phenotype and further indicate that this effect is mediated through the opposite regulation of ZEB1/ZEB2 and miR-200b and miR-200c. Furthermore, these results suggest a plausible etiologic explanation for the progressive pulmonary fibrosis, a frequent adverse condition associated with the therapeutic use of mTOR inhibitors. Cancer Res. 73(22): 6621–31. © 2013 AACR.

Introduction

The epithelial-to-mesenchymal transition (EMT) is a reversible embryonic transdifferentiation program that converts fully differentiated epithelial cells into fibroblastoid or mesenchymal cells (1). Fundamental to metazoan development, this process is characterized by profound phenotypic alterations, including disruption of cell–cell contacts, loss of cell polarity, and acquisition of migratory and invasive abilities. Besides its role in normal development, EMT contributes to tissue regeneration after injury. Recently, evidence for a critical role for EMT in pathologic settings such as fibrosis and carcinoma progression to metastasis was provided, demonstrating that this program can be hijacked by cancer cells to disseminate and colonize distant organs (2). However, macro-metastatic development is often accompanied by redifferentiation of the disseminated tumor cells, suggesting that cancer cell dissemination through EMT must be followed by the reverse process, mesenchymal-to-epithelial transition (MET), for efficient metastatic development (3, 4). Depending on the biologic context, EMT was classified into three different subtypes: Type I refers to physiologic EMT that occurs during development; Type II takes place during wound healing, tissue regeneration, and organ fibrosis; and Type III is associated with metastatic dissemination of cancer cells (2, 5).

EMT is triggered by various cytokines or growth factors including TGF-β, EGF, IGF (insulin-like growth factor), PDGF (platelet-derived growth factor), and HGF (hepatocyte growth factor) but also insults such as mechanical stress or hypoxia. The vast majority of these inducers converge on the activation of one or more transcription repressors, recognized as EMT inducers. This group of transcription factors, including TWIST1 and TWIST2, SNAI1 and SNAI2, and ZEB1 and ZEB2, represses directly or indirectly the E-cadherin (CDH1) promoter and provokes important changes in gene expression programs, resulting in the extinction of epithelial markers (E-cadherin, OC11, ZO-1, cytokeratin, etc.) and the acquisition of mesenchymal traits, including the expression of specific

Authors’ Affiliations: 1Université Lyon 1, ISPB; 2CNRS UMR5286, INSERM U1052, Centre de Recherche en Cancérologie de Lyon, Centre Léon Bérard; 3CIRI INSERM U1111, CNRS UMR3308, ENS Lyon, Lyon; 4INSERM, U823, Université Joseph Fourier-Grenoble 1, Institut Albert Bonniot; 5In Ovo, Grenoble, France; and 6Inositide Laboratory-Signaling Program, Babraham Institute-Babraham Research Campus, Babraham, Cambridge, United Kingdom

Note: Supplementary data for this article are available at Cancer Research Online (http://cancerres.aacrjournals.org/).

Corresponding Authors: Marc Billaud, Institut Albert Bonniot, CRI INSERM/U1111, Université Joseph Fourier, BP 170, F-38042, Grenoble Cedex 9, France. Phone: 33-4-76-54-95-71; E-mail: marc.billaud@ujf-grenoble.fr; and Ivan Mikaelian, Centre de Recherche en Cancérologie de Lyon, F-69008 Lyon, France. Phone: 33-4-69-16-66-25; Fax: 33-4-78-78-27-20; E-mail: ivan.mikaelian@lyon.unicancer.fr

doi: 10.1158/0008-5472.CAN-13-0560

©2013 American Association for Cancer Research.
markers (vimentin, N-cadherin, PAI-1, FN1, etc.; ref. 1). Furthermore, cells undergoing EMT develop stem cell-like features such as the ability to self renew (6, 7). TGF-β is the prototypic EMT inducer (8). This pleiotropic cytokine activates the TGF-β pathway after binding to the serine/threonine kinase receptors TGFβRI and TGFβRII at the plasma membrane. Once activated, the receptor complex propagates the signal through phosphorylation of the SMAD2/3 transcriptional regulators, which, after translocation to the nucleus, oligomerize with SMAD4 and activate a first wave of target genes (9). Alternative noncanonical pathways have also been described to participate in TGF-β signaling and to promote EMT (10). One of these pathways links TGFβRII activation and tight junction dissolution via phosphorylation of the TGFβRII-associated polarity protein PAR6, recruitment of the ubiquitin ligase SMURF1 and RHOA proteasomal degradation (11).

Given the involvement of EMT in various pathophysiologic mechanisms, it is important to improve our basic knowledge of the various signaling pathways and factors involved in this process. Indeed, identification of new therapeutic targets is urgently needed to develop original treatments against cancer progression because metastasis is the main cause of death among patients with cancer. We therefore conducted a siRNA screen targeted at the human kinome with the aim of identifying new EMT effectors. This screen allowed us to uncover a key role for the master kinase mTOR as part of the mTORC1 complex in the maintenance of the epithelial architecture.

Materials and Methods

Cell culture and siRNA transfection

The mammary epithelial cell lines MCF10A, MCF12A, MCF7, and MDA-MB-231 were obtained from the American Type Culture Collection (ATCC). Cell lines were authenticated in July and September 2013 by STR (US8/UMS344; BioSciences) or SNP (Multiplexion) analysis. MCF10A and MCF12A, two spontaneous immortalized but nontransformed cell lines, were grown in Dulbecco’s Modified Eagle Medium (DMEM)/F12 supplemented as described previously (12). MCF7 and MDA-MB-231 cells were cultured as recommended by the ATCC. The siRNA screening was conducted in MCF10A using a library of 580 real-time PCR (RT-PCR)—validated siRNAs targeting kinases and associated proteins (Human Validated Kinase siRNA Set V1.0. QIAGEN) as described in Supplementary Methods. Transfection with siRNAs (10 nmol/L) was performed with RNAiMAX (Invitrogen) as transfection reagent (see Supplementary Methods).

EMT reporter and shRNA lentivectors

Reporter constructs pVFir and pERuc used to quantitate EMT were constructed by fusing the human CDH1 promoter region (nt −1,629 to −47 relative to the translation start site) and the human VIM promoter region (nt −1,115 to −65) to the coding region of the firefly luciferase and the Renilla luciferase, respectively. These chimeric genes were then cloned into the simian immunodeficiency virus-based lentivector pSIV-gaMES-ISA (13). Viral particles pseudotyped with the vesicular stomatitis virus glycoprotein envelope were produced as described previously (13). Forty-eight hours after infection with pVFir and pERuc, expression of the firefly and Renilla luciferase expression was measured with a microplate luminometer (Luminoskan Ascent; Labsystems) using the Dual-Glow luciferase assay system (Promega). The EMT index (EMTI) was calculated as the ratio of firefly to Renilla luminescence. Stable silencing of mTOR, RPTOR, and RICTOR was achieved after transduction of cells with lentiviral vectors obtained from Addgene (reference numbers 1864, 1855, 1856, 1857, 1858, 1853, and 1854; ref. 14).

Quantitative RT-PCR

Total RNA was extracted with TRIzol reagent (Invitrogen) according to the manufacturer’s instructions. Total RNA was used for complementary DNA synthesis using the SuperScript II reverse transcriptase system (Invitrogen). mRNAs were then quantified by quantitative RT-PCR using the SYBER Green PCR system on a StepOnePlus instrument (Applied Biosystems). Primer sequences are given in Supplementary Methods. microRNA (miRNA) mir-200b and mir-200c were quantified by reverse transcription using the TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems) and quantitative RT-PCR performed with TaqMan miRNA assays hsa-miR-200c-3p, hsa-miR-200b-3p, and RNU44 as the endogenous control (Applied Biosystems).

Immunofluorescence, F-actin staining, and immunoblotting

For immunofluorescence, cells were fixed with 4% paraformaldehyde in PBS, permeabilized with 0.5% Triton X-100 in PBS, and labeled with fibronectin-specific antibody (IST4 1/100; Sigma) and DyLight 488 anti-mouse secondary antibody (Jackson ImmunoResearch). For F-actin staining, cells were labeled with phalloidin-Atto 488 (Sigma-Aldrich). Images were captured by fluorescence imaging (Axioskop 2; Carl Zeiss) or by confocal laser scanning microscopy (FV10i; Olympus). For immunoblotting, we used specific antibodies directed against vimentin (clone V9; DAKOCytomation), E-cadherin, and N-cadherin (BD Transduction Laboratories), FN1 (clone IST4; Sigma), 4E-BP1, phospho–4E-BP1 (S65), S6K, phospho-S6K1 (T389), RICTOR, RPTOR, mTOR, ZEB1, and SNAI2 (Cell Signaling Technology), and HRP-conjugated goat anti-mouse and goat anti-rabbit secondary antibodies (Roche Applied Science).

Migration assays

Migration rates were studied using the Transwell assay. Transwells (BD Biosciences) were coated overnight with a 25 μg/ml solution of rat-tail collagen (Roche Applied Science) in 0.2% acetic acid (v/v). Migration was assayed with 75,000 cells for two and a half hours in 24-well plates. Migrated cells located on the lower side of the Transwells were fixed with 4% paraformaldehyde and stained with crystal violet. Experiments were carried out in triplicate, and for each Transwell, three microscopic fields were counted.

In ovo invasion assay

Fertilized white Leghorn eggs (SFPA) were incubated at 38°C with 60% relative humidity for 10 days. At this stage (E10),
the chorioallantoic membrane was dropped by drilling a small hole through the eggshell into the air sac and a 1 cm² window was cut in the eggshell above the chorioallantoic membrane. MCF10A cells were labeled with VybrantTM DiO (Molecular Probes), resuspended in serum-free DMEM/F12, and $1 \times 10^6$ cells were loaded onto the chorioallantoic membrane before the eggs were returned to the incubator. At E19 the lower chorioallantoic membrane was collected and fixed in 4% formaldehyde in PBS to evaluate the number of invasive nodules using a Leica Macrofluor fluorescent microscope (Optimal).

Results

Identification of novel EMT regulators using a siRNA screen targeting the human kinase

Our goal was to identify novel kinases involved in EMT, either by triggering EMT per se or by inhibiting EMT induced by TGF-β. For this purpose, we performed a siRNA screen using the mammary epithelial cell line MCF10A as this nontumorigenic human cell line is a robust model for EMT induction (11, 15). MCF10A cells lose their epithelial phenotype and acquire the characteristic traits of mesenchymal cells when treated with various EMT inducers, including TGF-β, or upon overexpression of specific transcription factors (e.g., SNAI1, SNAI2, and TWIST1). To easily and quantitatively measure EMT, we set up a dual luciferase reporter system (Fig. 1A). Two lentiviral reporters were constructed that fused the vimentin promoter to the firefly luciferase coding sequence (pVFir) and the E-cadherin promoter to the Renilla luciferase open reading frame (pERuc). We choose E-cadherin and vimentin because these two proteins are typical markers of EMT that have been extensively used to monitor this process both in vitro and in vivo. In addition, as vimentin and E-cadherin are oppositely regulated during EMT, we believed that the combined use of

Figure 1. Description and validation of the EMT readout designed for the screen. A, schematic representation of the pVFir and pERuc lentiviral reporter constructs used in this study and the expected flip between E-cadherin and vimentin expression in cells undergoing EMT or MET. B, E-cadherin and vimentin expression were assayed in MCF7 and MDA-MB-231 cells by immunoblotting. C, firefly and Renilla luciferase expression after transduction of the pVFir and pERuc vectors in the MCF7 (epithelial) and MDA-MB-231 (mesenchymal) cell lines. D, calculation of the EMTi for MCF7 and MDA-MB-231 with luciferase values obtained from C. E, validation of EMTi with the mammary epithelial cell line MCF10A undergoing EMT after treatment with increasing amounts of TGF-β for 48 hours. F, E-cadherin and vimentin expression in MCF10A cells treated for 72 hours with the indicated amount of TGF-β were evaluated by immunoblotting. Experiments were carried out in triplicate. Error bars, SD. LTR, long terminal repeat; LTRsin, LTR with deletion in the U3 region; VIM, vimentin; ECAD, E-cadherin; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
these reporters would provide a reliable measure of the EMT process (Fig. 1A). These two constructs were assayed with two human mammary cancer cell lines, the epithelial and noninvasive MCF7 cell line that expresses E-cadherin, but lacks vimentin and the metastatic MDA-MB-231 cell line that has switched from E-cadherin to vimentin expression (Fig. 1B). As expected, E-cadherin promoter activity was high in MCF7 but low in MDA-MB-231 cells. Conversely, much stronger vimentin promoter activity was observed in MDA-MB-231 than in MCF7 cells (Fig. 1C). To quantify these effects, we calculated the EMT index as the ratio of the vimentin to E-cadherin promoters activity. This index proved to be a robust indicator of the status of the MCF7 and MDA-MB-231 cell lines with respect to EMT (Fig. 1D). We further validated this index with the nontransformed mammary epithelial cell line MCF10A treated with increasing concentrations of TGF-β. We showed that, along with the respective down- and upregulation of E-cadherin and vimentin protein levels, the EMT index increased in a dose-dependent manner upon addition of this cytokine confirming that we provided a sensitive and easily measurable readout of EMT induction (Fig. 1E and F).

Using this system, we screened a commercially available collection of validated siRNAs targeting the majority of human kinases (Human Validated Kinase siRNA Set V1.0; QIAGEN). The screening was carried out with MCF10A cells treated with or without TGF-β (see Supplementary Methods and Supplementary Fig. S1 for details of the screening procedure). The first round of screening allowed us to identify the first group of kinases that, when silenced, inhibited TGF-β-induced EMT (the “pro-EMT” group; Supplementary Tables S1–S3). Among these kinases, some have previously been implicated in EMT. This is the case for ABL, SRC, CK2β, HIP2, LYN, PKACA, MAP3K7 (TAK1), and MAPK1 (ERK2). New candidates for a role in EMT were further tested with two additional siRNAs per gene. Within the “pro-EMT” group, we were not able to identify any kinase showing coherent results with three different siRNAs (Supplementary Table S5). However, within the pro-MET group, the four kinases PDK2, SGK2, STK32, and mTOR (FRAP1) were validated with a total of three distinct siRNAs (from screen#1 and screen#2) according to the chosen criteria (Supplementary Table S4). Thus, considering the central role of mTOR in several key processes linked to cancer and the availability of pharmacologic inhibitors, we sought to further validate the RNAi observations by focusing on mTOR.

**mTOR inhibition induces EMT morphologic traits and markers**

Our siRNA screening indicated that the master kinase mTOR was required to maintain the epithelial phenotype. Accordingly, silencing of mTOR with two siRNAs (Fig. 2A) produced a more than 3-fold increase in EMTi, matching the EMT induction obtained through the silencing of RHOA, which was used as a control (Fig. 2B; ref. 11). As expected, mTOR silencing was accompanied by a drop in S6K1 phosphorylation, indicating that mTOR activity was impaired (Supplementary Fig. S4A). Then, we sought to confirm these findings using two pharmacologic mTOR inhibitors, rapamycin and PP242, the latter compound being a newly designed selective ATP competitive inhibitor (16). As with mTOR-targeting siRNAs, both rapamycin and PP242 treatments induced a 2- to 3-fold increase in EMTi and, as expected for mTOR inhibitors, a simultaneous reduction in S6K1 phosphorylation (Fig. 2C and D). Titration

![Figure 2. mTOR inhibition triggers EMT](image-url)
experiments using a large range of concentrations were also performed and confirmed the pro-EMT effect of these mTOR inhibitors (Supplementary Fig. S2A and S2B). To further validate these findings, MCF10A cells were grown in medium supplemented with PP242. As expected, treatment with 400 nmol/L of PP242 resulted in reduced cell proliferation (Supplementary Fig. S2C and S2D). After 4 to 5 days of treatment, phenotypic changes were observed that were even more noticeable after day 10 (Fig. 3A). Cells progressively lost their typical epithelial morphology and their ability to grow in clusters, adopting a mesenchymal phenotype at high and low densities, and grew isolated with a flat and spindle-like morphology (Fig. 3A). A similar phenotypic transformation was observed when cells were treated with rapamycin instead of PP242 (Supplementary Fig. S3A). At the protein level, S6K1 and 4E-BP1, two substrates of mTOR, were hypophosphorylated upon long-term PP242 treatment (Fig. 3B). Immunofluorescence experiments confirmed these findings, demonstrating an accumulation of FN1 and the reorganization of cortical actin into stress fibers typical of mesenchymal cells (Fig. 3C). Consistently, quantitative RT-PCR (qRT-PCR) analysis (Fig. 3D) revealed a downregulation of epithelial transcripts (MUC1, CDH3, TJP3, CDH1, and OCLN) and the upregulation of mRNAs specific to mesenchymal cells (CDH2, VIM, SERPINE1, and FN1). Thus, prolonged mTOR kinase inhibition endowed epithelial cells with mesenchymal traits and markers.

**EMT triggered by mTOR inhibition is TGF-β independent**

Interestingly, silencing of mTOR with siRNAs potentiated TGF-β–induced EMT, as revealed by a 3-fold increase in EMTi compared with TGF-β alone (Fig. 4A). In addition and similar to siRNAs, both rapamycin and PP242 cooperated with TGF-β to further activate EMT in a more than additive manner (Fig. 4B). In all cases, there were consistent 2- to 3-fold increases in EMTi, whether cells were treated with siRNAs or with mTOR chemical inhibitors. These results suggested that EMT induced by mTOR inhibition is independent of the TGF-β pathway. To further address this point, we challenged rapamycin- and PP242-induced EMT with SB431542, a strong and specific inhibitor of TGFBR1. SB431542 affected the basal EMT status of MCF10A, as shown by a 2-fold decrease in EMTi upon treatment (Fig. 4C). This effect was most probably due to inhibition of traces of TGF-β activity present in the culture medium. As expected, SB431542 severely inhibited TGF-β–dependent EMT activation. However, inhibition of the TGF-β receptor failed to impair rapamycin or PP242 induction of EMT, because these drugs still promoted a...
3-fold increase in EMTi as compared with cells treated with SB431542 alone. We also provided evidence that mTOR inhibition did not activate the TGF-β pathway downstream of TGFBR1. Using a MCF10A cell line carrying an integrated TGF-β–specific luciferase reporter gene, we showed that rapamycin was inefficient in activating this pathway, even at high concentrations (Fig. 4D). Altogether, these experiments show that EMT induction resulting from mTOR inhibition is independent of TGF-β.

mTORC1 inhibition promotes EMT

mTOR is found in two different complexes, mTORC1 and mTORC2, which relay their various effects within cells (17). Because rapamycin preferentially targets mTOR within the mTORC1 complex, we anticipated that the effect observed on EMT was due to mTORC1 inhibition. To address this point, we invalidated mTORC1 and mTORC2 by targeting RPTOR and RICTOR, respectively, with two specific short hairpin RNAs (shRNA; Fig. 5A). Although MCF10A cells silenced for RICTOR showed no morphologic changes, cells silenced for RPTOR adopted mesenchymal traits with a flat and scattered phenotype (Fig. 5B). In addition, vimentin expression increased upon RPTOR silencing, in agreement with induction of a mesenchymal state (Fig. 5B). Measuring EMTi further confirmed that RPTOR silencing triggered EMT, whereas the knockdown of RICTOR did not exert a similar effect (Fig. 5C). The same results were obtained from experiments carried out with MCF12A cells, another nontransformed human mammary cell line (Supplementary Fig. S3B and S3C). In addition, silencing of mTOR or RPTOR with siRNAs also promotes EMT in MCF10A.
mTORC1 inhibition promotes cell migration and invasion

Next, we addressed the consequences of mTORC1 inhibition on cell migration and invasion. Using Transwell assays, we obtained evidence that cells depleted for either mTOR or RPTOR, displayed increased motility compared with controls and RICTOR shRNA (Fig. 6A and B). To study invasion, we used the chicken chorioallantoic membrane invasion assay. As expected for nontransformed cells, control MCF10A cells were unable to invade the embryo and reach the lower side of the chorioallantoic membrane following inoculation on the upper side. On the other hand, MCF10A cells chronically treated with PP242 or expressing shRNA against RPTOR were able to invade and colonize the lower side of the chorioallantoic membrane (Fig. 6C and D). Therefore, mTORC1 blockade with shRNA or pharmacologic compounds enhances the migratory and invasive abilities of mammary epithelial cells.

ZEB proteins and miR-200 family members are oppositely regulated upon mTORC1 inhibition

To better characterize the molecular mechanisms linking mTORC1 inhibition to EMT induction, we analyzed the expression of known pro-EMT transcription factors. The prototypic factors TWIST1, SNAI1, SNAI2, ZEB1, and ZEB2 were tested, as well as TCF4 and YB-1, which have also been shown to induce EMT (18–20). qRT-PCR revealed that both ZEB1 and ZEB2 mRNAs were significantly upregulated, whereas SNAI1, SNAI2, TWIST1, TCF4, and YB-1 mRNAs were not affected in MCF10A following sustained PP242 treatment (Fig. 7A). Upregulation of ZEB1 was also evident at the protein level, whereas SNAI2 was not affected (Fig. 7B). To generalize our findings, activation of ZEB1 following mTORC1 invalidation was also addressed by qRT-PCR in various mammary cell lines, including primary human mammary epithelial cells (HMEC) and immortalized human bronchial epithelial cells (HBEC-3KT). In the MCF10A, MCF12A, HMEC, HMEC-T, HMEC-TR, and HBEC-3KT cell lines, ZEB1 mRNA levels were significantly increased upon mTOR and RPTOR silencing with siRNAs, but remained unchanged in MCF7 and MDA-MB-231 cell lines (Supplementary Fig. S5). This indicates that although it is shared by several cell lines, including primary cells and normal immortalized cell lines, the effect of mTORC1 silencing on ZEB1 expression is probably dependent on the mutational status of the cells.

Because ZEB1 and ZEB2 mRNAs are well-described targets of miR-200 miRNAs, we studied the effects of mTOR inhibition on the expression of these miRNAs. The human miR-200 family of miRNAs is organized into two clusters located on human chromosomes 1 and 12, which encode miR-200a/200b/429 and miR-200c/141, respectively. Because the miRNAs within each cluster are coregulated (21), we focused on miR-200b and miR-200c and measured their relative expressions by qRT-PCR. As shown in Fig. 7C and D, the expression of both miR-200b and
miR-200c was repressed upon silencing of RPTOR with shRNA, chronic inhibition of mTOR activity with PP242 or silencing RPTOR and mTOR with siRNAs. Thus, these results indicate that mTORC1 inhibition induces EMT through the activation of ZEB1/2 expression with a concomitant downregulation of miR-200 miRNAs.

Discussion

EMT is a cell differentiation program switched on during embryonic development and wound healing. This process, crucial for the physiologic control of epithelial plasticity, is also abnormally reactivated in various pathologic situations and contributes to the genesis of fibrosis and carcinoma spreading. In this study, we designed an original screening method to identify new EMT regulators. To reliably quantify EMT, we set up a dual luminescent EMT-reporter system based on lentiviral vectors that comprised either the vimentin or the E-cadherin promoter regions fused to different luciferase coding sequences. Using this experimental strategy, we performed a kinome-wide siRNA screening in the human mammary cell line MCF10A and uncovered a new role for the mTORC1 complex in the maintenance of the epithelial phe- notype. RNAi-mediated silencing of mTOR or RPTOR, as well as inhibition of mTORC1 kinase activity with chemical inhibitors, promoted EMT. This conclusion was drawn from the observed up- and downregulation of mesenchymal and epithelial markers, changes in cell morphology, and increased migratory and invasive abilities that constitute altogether specific EMT features. Further exploration of the mechanisms involved revealed a direct correlation between the inhibition of mTORC1 and the coordinated upregulation of ZEB transcriptional repressors and downregulation of miR-200 family members, two molecular events known to trigger EMT. In addition, activation of ZEB1 upon mTOR or RPTOR silencing was also observed in primary HMEC and in several immortalized epithelial cell lines, but was not found in two cancer-derived cell lines, suggesting that genetic alterations may modify cell signaling properties and the ensuing responsiveness of malignant cells to mTORC1 inhibition. The screening of a larger series of tumor cell lines to correlate the effects mTORC1 inhibition on EMT with mutations causally involved in the cancer process would deserve to be conducted in the future to address this question.

TOR is a master kinase activated in response to various exogenous stimuli: growth factors, high concentration of glucose and amino acids, inflammation, hypoxia, genotoxic stress, and energy starvation. mTOR stimulation results in the upregulation of metabolism and cell growth, mainly through protein and lipid syntheses (22). Recent reports have suggested a role for mTOR in the EMT process, but with conflicting results (23–26). According to Gulhati and colleagues, mTORC1 and

Figure 6. mTORC1 inhibition stimulates cell migration and invasion. Migration of MCF10A cells stably expressing control (CTL), mTOR-, RICTOR-, or RPTOR-specific shRNA were analyzed using a Transwell migration assay. A, representative images of migrated cells are given for each cell population. B, quantification of migrated cells. C and D, chicken chorioallantoic membrane invasion assays of MCF10A cells expressing CTL versus RPTOR shRNA or treated for 10 days with DMSO versus PP242 (400 nmol/L). C, representative images showing the lower chorioallantoic membrane of eggs inoculated with fluorescently labeled cells; D, analysis of chorioallantoic membrane assay experiments giving the proportion of eggs with invaded lower chorioallantoic membrane and the average number of foci per egg. Error bars, SD.

Mikaelian et al.  Cancer Res; 73(22) November 15, 2013  6628

Cancer Research

Downloaded from cancerres.aacrjournals.org on August 5, 2015. © 2013 American Association for Cancer Research.
mTORC2 complexes positively regulate EMT, as well as the motility and metastatic abilities of colorectal cancer cells (23). In addition, Lamouille and colleagues reported that both mTOR complexes are rapidly activated in the nontransformed mouse mammary cell line NMuMG upon TGF-β treatment (24, 25). Although these authors clearly demonstrated that mTORC2 is required to undergo EMT, their study argued against a major role for mTORC1 in this process, because rapamycin did not affect the TGF-β–induced EMT phenotype. However, in agreement with our findings, a pro-EMT effect of mTORC1 inhibition was suggested by a more recent study (26). Using syngenic MCF10A cell lines with an activating mutation in the PIK3CA gene, Wallin and colleagues showed that pharmacologic mTOR inhibition potentiated EMT and the invasive phenotype resulting from activation of the PI3K pathway. Because mTOR controls cell proliferation, our study suggests a link between growth inhibition and induction of an invasive phenotype. This hypothesis is consistent with the apparently opposite activities of other EMT inducers. First, TGF-β has long been acknowledged for both its tumor-suppressive and proinvasive activities (27). More recently, it has been found that the transcription/translation factor YB-1 is both an inhibitor of cell growth and an EMT inducer. These data have raised the notion that reduced cell proliferation and enhanced invasiveness represent the two faces of a coordinated process (28). In agreement with these latter observations, our study provides evidence that mTORC1 suppresses EMT and stabilizes the epithelial phenotype.

Ever since, the discovery of rapamycin as an immunosuppressive drug, structural analogues with better pharmacokinetic profiles, have been developed and are now used in chemotherapy. Two of these “rapalogs,” temsirolimus and everolimus, were recently approved by the U.S. Food and Drug Administration for the treatment of metastatic renal cell carcinoma. However, despite their recognized beneficial effect on patients’ survival, these drugs have several side effects, including hypercholesterolaemia, hypertriglyceridaemia, thrombocytopenia, and interstitial lung diseases (ILD). ILD refers to a number of pathologic disorders affecting the tissue located between the air sacs of the lung. Often called interstitial pulmonary fibrosis, ILD is characterized by chronic inflammation and progressive fibrosis of the pulmonary interstitium. A very high frequency of patients (up to 36%) treated with rapalogs were found to have radiographic evidence of ILD, but the pathology often regressed upon discontinuation of mTOR-targeted treatment (29–35). Interestingly, there is mounting evidence that aberrant activation of EMT could contribute to pulmonary fibrosis through the transdifferentiation of alveolar
epithelial cells into proliferating fibroblasts (36–39). Accordingly, cells coexpressing epithelial and mesenchymal markers were detected in biopsies of fibrotic lungs (38). In addition, the activation of signaling pathways involved in EMT, in particular TGF-β or Wnt pathways, was also reported in the lungs of patients affected by pulmonary fibrosis (36, 40, 41). Moreover, rat bronchial epithelial cells (RL-65) treated with sirolimus displayed mesenchymal traits (42). Therefore, our results suggest the intriguing idea that the inhibitory action of rapamycin on mTORC1 may promote the EMT of bronchoalveolar cells, thereby contributing to the ILD pathophysiologic process.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Authors’ Contributions
Conception and design: I. Mikaelian, M. Malek, M. Billaud
Development of methodology: I. Mikaelian, M. Malek, J. Viallet, M. Billaud
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): I. Mikaelian, M. Malek, R. Gadet, J. Viallet, A. Garcia, A. Girard-Gagnepain, C. Hesling
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): I. Mikaelian, J. Viallet, A. Girard-Gagnepain, C. Hesling, P. Gonzalo, R. Rimokh, M. Billaud
Writing, review, and/or revision of the manuscript: I. Mikaelian, J. Viallet, C. Hesling, P. Gonzalo, M. Billaud

Administrative, technical, or material support (i.e., reporting and organizing data, constructing databases): I. Mikaelian, R. Rimokh

Study supervision: I. Mikaelian, G. Gilet, R. Rimokh, M. Billaud

Acknowledgments
The authors thank Odile Fillol-Cochet, Laurence Lafanichère, and Florence Solari for helpful discussion and Renaud Prudent and Sylvie Mazoyer for critical reading of the article. The authors also thank Nadège Goutagny for the gift of HMEC cells and Christophe Vanbelle and Annabelle Bouchardon (CéCILE—SFR Santé Lyon-Est) for help with confocal microscopy.

Grant Support
This work was supported by a grant from the Ligue Nationale Contre le Cancer (Programme CIT; Corte d’Identité des Tumeurs). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received February 22, 2013; revised August 18, 2013; accepted August 23, 2013; published OnlineFirst September 27, 2013.

References


Genetic and Pharmacologic Inhibition of mTORC1 Promotes EMT by a TGF-β–Independent Mechanism

Ivan Mikaelian, Mouhannad Malek, Rudy Gadet, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-13-0560

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2013/09/27/0008-5472.CAN-13-0560.DC1.html

Cited articles
This article cites 42 articles, 14 of which you can access for free at:
http://cancerres.aacrjournals.org/content/73/22/6621.full.html#ref-list-1

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.